期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 21, 期 1, 页码 99-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2011.09.001
关键词
Gastric cancer; Chemotherapy; Operable
资金
- Roche
- Novartis
- Merck Serono
- Amgen
- Merck Sharpe
- Dohme
- Sanofi-Aventis
- National Institute for Health Research (NIHR) Biomedical Research Center
Radical surgery offers the only chance of cure for patients with operable gastric cancer; however, outcomes remain generally poor due to a high rate of relapse post gastric surgery. Multimodality therapy using chemotherapy, radiation or a combination of both have been evaluated in different parts of the world to improve outcomes from surgery alone. Perioperative chemotherapy is generally preferred in Europe in contrast to postoperative chemoradiation in the US or adjuvant fluoropyrimidine chemotherapy in East Asia. Regardless of these variations, systemic chemotherapy consistently results in a survival benefit when used in multimodality treatment of operable gastric cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据